Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
NCT01508364 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2015-01-21
Summary
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.
Conditions
- Carcinoma, Renal Cell
Interventions
- DRUG
-
Sorafenib (Nexavar, BAY 43-9006)
Dosage according to label or at discretion of the attending physician
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-07-31
- Primary Completion
- 2013-12-31
- Completion
- 2013-12-31
Countries
- Germany
More Related Trials
-
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
NCT01412671 ·Status: COMPLETED
-
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
NCT00492986 ·Status: COMPLETED ·Phase: PHASE3
-
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
NCT01411423 ·Status: COMPLETED
-
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
NCT00079612 ·Status: COMPLETED ·Phase: PHASE2
-
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
NCT00876382 ·Status: COMPLETED
-
Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00110344 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
NCT00111020 ·Status: COMPLETED ·Phase: PHASE3
-
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
NCT00392821 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Regulatory Post Marketing Surveillance Study on Nexavar®
NCT01012011 ·Status: COMPLETED
-
Sorafenib Dose Escalation in Renal Cell Carcinoma
NCT00618982 ·Status: COMPLETED ·Phase: PHASE2
-
BAY43-9006 Phase II Study for Renal Cell Carcinoma
NCT00661375 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Elderly mRCC
NCT01728948 ·Status: COMPLETED
-
Long-term Extension From RCC Phase II (11515)
NCT00586495 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
NCT00586105 ·Status: COMPLETED ·Phase: PHASE3
-
Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma
NCT01982097 ·Status: COMPLETED
-
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
NCT00073307 ·Status: COMPLETED ·Phase: PHASE3
-
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
NCT00352859 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
NCT00478114 ·Status: COMPLETED ·Phase: PHASE3
-
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
NCT00117637 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
NCT00917462 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
NCT00126503 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
NCT06860386 ·Status: SUSPENDED ·Phase: PHASE2
-
Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
NCT00602862 ·Status: COMPLETED ·Phase: NA
-
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
NCT00942682 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
NCT00848640 ·Status: COMPLETED ·Phase: PHASE2